Hypoxia: Clinical Trials

8 trials for Hypoxia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 terminated. 8 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Terminated 8
Phase 24Terminated 4

Follow Hypoxia: new trials by email Literature Review of Hypoxia trials Research Report on Hypoxia

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Metformin Treatment in Infants After Perinatal Brain Injury
Metformin Hydrochloride - Hypoxic Ischemic Encephalopathy of Newborn, Premature Birth
Phase 1TerminatedThe Hospital for Sick Children12023-05-022024-03-07
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Oral NKT2152 - ccRCC, Clear Cell Renal Cell Carcinoma
Phase 1 / Phase 2TerminatedNiKang Therapeutics, Inc.1202021-10-262025-11-12
TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA
2-Iminobiotin - Cardiac Arrest, Hypoxic Ischemic Brain Injury
Phase 1 / Phase 2TerminatedAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)212016-05-012021-02-18
Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy
Topiramate, Placebo - Hypoxic Ischemic Encephalopathy
Phase 1 / Phase 2TerminatedKristin R Hoffman342013-02-012024-06-11
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
Clostridium novyi-NT spores - Solid Tumor Malignancies
Phase 1TerminatedBioMed Valley Discoveries, Inc52011-04-012016-01-20
One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy
Clostridium novyi-NT spores - Tumors
Phase 1TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins22006-07-012016-10-14
Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome
pentoxifylline - Hepatopulmonary Syndrome
Phase 1TerminatedUniversity of Alabama at Birmingham92004-06-012015-03-09
Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation
nitric oxide for inhalation, Oxygen - Lung Disease, Hypoxemia
Phase 1 / Phase 2TerminatedMallinckrodt72002-05-012016-10-19

Narrower conditions

Hypoxia-Ischemia, Brain (3)  ·  Necrosis (2)  ·  Neoplasms (2)  ·  Acidosis, Respiratory (1)  ·  Carcinoma, Renal Cell (1)  ·  Colonic Neoplasms (1)  ·  Fibrosis (1)  ·  Heart Arrest (1)  ·  Hepatopulmonary Syndrome (1)  ·  Kidney Neoplasms (1)  ·  Lung Diseases (1)  ·  Lung Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Pancreatic Neoplasms (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (8)  ·  Signs and Symptoms (8)  ·  Signs and Symptoms, Respiratory (8)  ·  Brain Diseases (3)  ·  Brain Ischemia (3)  ·  Cardiovascular Diseases (3)  ·  Central Nervous System Diseases (3)  ·  Cerebrovascular Disorders (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)  ·  Hypoxia, Brain (3)  ·  Nervous System Diseases (3)  ·  Pathologic Processes (3)  ·  Respiratory Tract Diseases (3)  ·  Urogenital Diseases (3)

Interventions

2-iminobiotin (1)  ·  Bacterial Load (1)  ·  Endothelium-Dependent Relaxing Factors (1)  ·  Inhalation (1)  ·  Metformin (1)  ·  Nitric Oxide (1)  ·  Oxygen (1)  ·  Pentoxifylline (1)  ·  Topiramate (1)

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  BioMed Valley Discoveries, Inc (1)  ·  Kristin R Hoffman (1)  ·  Mallinckrodt (1)  ·  NiKang Therapeutics, Inc. (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  The Hospital for Sick Children (1)  ·  University of Alabama at Birmingham (1)

Countries

United States (6)  ·  Canada (1)  ·  Netherlands (1)

Top investigators

Brian T Kalish, MD (1)  ·  Janneke Horn, MD, PhD (1)  ·  Kristin R Hoffman, MD (1)  ·  Luis A Diaz, MD (1)  ·  Michael B Fallon, MD (1)  ·  Waldemar Carlo, MD (1)

Results publications

PMID 18668653, PMID 19183804

NIH funding

R03DK065958 (1)